SynOx takes rare tumour treatment to phase 3 with $75m Series B
Could SynOx's $75M Phase 3 Trial Be the Next Big Leap in TGCT Treatment?
Archives for April 29, 2024
Bristol Myers Squibb enlists Cellares amid industry manufacturing “land grab”
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable